Brokers Issue Forecasts for Kodiak Sciences Q1 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD) – Zacks Research issued their Q1 2027 EPS estimates for Kodiak Sciences in a note issued to investors on Wednesday, April 16th. Zacks Research analyst R. Department anticipates that the company will post earnings per share of ($0.91) for the quarter. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. Zacks Research also issued estimates for Kodiak Sciences’ FY2027 earnings at ($3.49) EPS.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $3.00 price target on shares of Kodiak Sciences in a research report on Monday, March 31st.

Kodiak Sciences Price Performance

NASDAQ KOD opened at $2.84 on Friday. The company has a market capitalization of $150.02 million, a price-to-earnings ratio of -0.78 and a beta of 2.40. Kodiak Sciences has a 12 month low of $1.92 and a 12 month high of $11.60. The company’s fifty day moving average price is $3.45 and its two-hundred day moving average price is $5.36.

Kodiak Sciences (NASDAQ:KOD) last released its earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.06.

Institutional Trading of Kodiak Sciences

Several institutional investors have recently added to or reduced their stakes in KOD. PNC Financial Services Group Inc. boosted its holdings in shares of Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock valued at $32,000 after buying an additional 2,988 shares during the period. American Century Companies Inc. boosted its stake in Kodiak Sciences by 6.2% in the fourth quarter. American Century Companies Inc. now owns 59,967 shares of the company’s stock valued at $597,000 after acquiring an additional 3,515 shares during the period. US Bancorp DE bought a new position in shares of Kodiak Sciences during the fourth quarter valued at approximately $40,000. Bank of New York Mellon Corp lifted its holdings in shares of Kodiak Sciences by 5.3% in the 4th quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company’s stock worth $976,000 after purchasing an additional 4,927 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Kodiak Sciences by 2.9% during the 4th quarter. Northern Trust Corp now owns 269,597 shares of the company’s stock valued at $2,682,000 after purchasing an additional 7,678 shares during the period. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.